Katherine Tsai, MD
Internal Medicine · Denver, CONPI 1316084205
Payments from drug & device makers
Across 771 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Novartis$887
- CSL Behring$846
- Sanofi$796
- plus $6K from 34 others
What the payments were for
- Food & beverage$15,11199%
- Education$1951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 121 | $3,013 |
| GSK | 92 | $1,764 |
| Regeneron Healthcare Solutions, Inc. | 92 | $1,693 |
| Novartis | 46 | $887 |
| CSL Behring | 50 | $846 |
| Sanofi | 38 | $796 |
| Genentech USA, Inc. | 41 | $792 |
| Pfizer | 30 | $563 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $550 |
| Teva Pharmaceuticals USA, Inc. | 30 | $462 |
| Amgen | 19 | $422 |
| Biocryst US Sales Co., LLC | 25 | $400 |
| Grifols USA, LLC | 17 | $388 |
| Pharming Healthcare, Inc. | 16 | $370 |
| Kaleo, Inc. | 15 | $308 |
| Galderma Laboratories, L.p. | 20 | $253 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $212 |
| Cycle Pharmaceuticals Inc | 9 | $202 |
| Incyte Corporation | 11 | $191 |
| AbbVie | 8 | $170 |
| Optinose US, Inc. | 11 | $164 |
| Lilly USA, LLC | 7 | $156 |
| Boehringer Ingelheim | 9 | $154 |
| Octapharma USA, Inc. | 4 | $95 |
| Greer Laboratories, Inc. | 3 | $64 |
| Novo Nordisk | 3 | $47 |
| Ionis Pharmaceuticals, Inc. | 2 | $43 |
| LEO Pharma Inc. | 2 | $42 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Arcutis Biotherapeutics, Inc. | 2 | $34 |
| Organon | 3 | $26 |
| Verona Pharma, Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Alk-abello, Inc | 1 | $21 |
| Biocryst Pharmaceuticals, Inc. | 1 | $19 |
| USWM, LLC | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Merck | 1 | $13 |
| Bio Products Laboratory USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,306 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 40 | $256,521 |
| NucalaMepolizumab | 14 | $66,031 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $62,678 |
| TezspireTezepelumab-Ekko | 13 | $57,208 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $45,533 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $26,530 |
| Spiriva RespimatTiotropium Bromide | 32 | $25,512 |
| SymbicortBudesonide/Formoterol Fumarate | 63 | $21,712 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 118 | $18,296 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $16,530 |
| Qvar RedihalerBeclomethasone Dipropionate | 36 | $16,130 |
| Epinephrine | 49 | $10,105 |
| Advair DiskusFluticasone Propion/Salmeterol | 16 | $7,955 |
| DuleraMometasone/Formoterol | 18 | $7,082 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 157 | $5,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta | $1,764 | $142,29294 claims |
| AstraZenecaTezspire, Symbicort | $3,013 | $78,92076 claims |
| Grifols USA, LLCGamunex-C | $388 | $62,67811 claims |
| Boehringer IngelheimSpiriva Respimat | $154 | $25,51232 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $462 | $16,13036 claims |
| MerckDulera | $13 | $7,08218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Denver
- Jason HenryDenver$7.3M
- Thomas StarkeyDenver$391K
- Matthew KoslowDenver$182K
- Keith HruskaDenver$167K
- Kenneth OleszekDenver$60K
- Robert KeithDenver$49K
- Elena AnisimovaDenver$36K
- Chase BlackfordDenver$30K
- Samuel BrownDenver$18K
- Saurabh MangalikDenver$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.